Additionally, the TFEB-mediated lysosomal degradation of GPX4 contributed to β-ELE-induced ferroptosis in NSCLC, providing a novel therapeutic strategy for NSCLC [29]. Here, GPX4 is linked to non-small cell lung carcinoma.